BWXT Q3 2026 Earnings Call Transcript

BWX Technologies reported Q3 revenue of $953 million, up 10% year over year, Adjusted EBITDA of $179.7 million, up 19%, and adjusted EPS of $1.26, up 26%. Management raised the low end of 2026 free-cash-flow guidance to $350 million while keeping adjusted EBITDA guidance at approximately $667 million, and expects high-single-digit to low-double-digit growth in adjusted EBITDA and EPS in 2027. The company cited an $8.6 billion backlog, a 50% capacity increase at its Cambridge facility, and new advanced-nuclear awards; it also noted 2027 margin-mix and pension-contribution headwinds.

Analysis

BWXT’s near-term earnings case is more credible than its commercial-nuclear upside case: core execution and better manufacturing utilization support 2027 growth, while large new-build awards remain contingent on allocating project-overrun risk among buyers, utilities, governments and vendors. The distinction matters for valuation—backlog and awarded defense work support visibility, but reactor pipeline should not be capitalized as firm revenue before orders and financing structures are executable.

The second-order risk is cash conversion. Earnings are expected to grow while free cash flow is only flat to slightly higher, with working-capital investment and elevated capacity spending absorbing part of the benefit. Favorable advance billings helped current cash flow; if billing milestones reverse or HPDU/enrichment ramps consume cash before customer payments, the market may discount reported EBITDA growth. PCG’s underused capacity offers upside through absorption, but only if commercial demand fills it without diluting margins. Government margin mix as new programs scale is another watch item.

Over the next 1–3 months, the naval multiyear pricing agreement, centrifuge demonstration and U.S. facility investment decision are tangible catalysts. Over 6–18 months, firm commercial awards—not selections, MOUs or management’s demand commentary—are the proof point. The contrarian caution: nuclear enthusiasm may be conflating BWXT’s strong established franchise with still-uncertain new-build timing. Conversely, treating all commercial opportunity as speculative misses the operating leverage available from existing capacity. No valuation data are supplied, so avoid a price-target claim.

Key Decisions for Investors

• Keep BWXT as a core exposure, but add on weakness rather than chase nuclear-theme momentum; the earnings trajectory is better supported than the new-build optionality.
• Treat a signed naval multiyear pricing agreement and evidence of PCG utilization/margin progression as near-term confirmation. Reassess if Government Operations margins contract as new programs scale or commercial growth fails to translate into improved segment margins.
• Track quarterly operating cash flow, working capital and advance billings against EBITDA growth. A sustained deterioration in cash conversion, or 2027 free cash flow below the company’s flat-to-slightly-higher outlook, would weaken the thesis.
• Do not underwrite large-reactor upside until firm supplier awards and project risk allocation are disclosed. A delay beyond the first half of 2027 in expected order conversion would challenge the timing of the commercial-growth narrative, though not by itself invalidate the core business.